- Home
- WF vs IONS Comparison
WF vs IONS Comparison
Compare WF & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WF | IONS |
|---|---|---|
| Founded | 1899 | 1989 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6B | 13.5B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | WF | IONS |
|---|---|---|
| Price | $61.53 | $80.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 22 |
| Target Price | N/A | ★ $83.64 |
| AVG Volume (30 Days) | 51.5K | ★ 2.1M |
| Earning Date | 03-04-2026 | 02-18-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ 20.51 | N/A |
| EPS | ★ 2.97 | N/A |
| Revenue | ★ $8,054,512,650.00 | $966,957,000.00 |
| Revenue This Year | N/A | $29.67 |
| Revenue Next Year | $4.37 | N/A |
| P/E Ratio | $6.75 | ★ N/A |
| Revenue Growth | ★ 23.56 | 20.41 |
| 52 Week Low | $29.44 | $23.95 |
| 52 Week High | $61.82 | $86.15 |
Technical Indicators
Market Signals| Indicator | WF | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 66.70 | 53.45 |
| Support Level | $56.60 | $74.20 |
| Resistance Level | $58.39 | $79.75 |
| Average True Range (ATR) | 1.47 | 3.31 |
| MACD | 0.24 | -0.06 |
| Stochastic Oscillator | 92.06 | 53.01 |
Price Performance
Historical ComparisonAbout WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.